The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse
Cancer · 2023-04 · 129 (7) · 1005-1016
DOI: 10.1002/cncr.34641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 27.01.2023. Verfasst von Yawen Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
The prognostic value of additional copies of chromosome 1q (1q gain/amplification [amp]) in multiple myeloma (MM) remains controversial. In the meantime, the kinetics of the response to MM therapy has long been an area of debate. Few studies have pointed out the relationship of response kinetics with cytogenetic abnormalities (CAs) in MM.
Methods
The authors retrospectively analyzed the data of 1068 real‐world newly diagnosed MM patients from a Chinese national medical center.
Results
Overall, 405 (51.9%) patients had 1q gain/amp, with aggressive clinical characteristics and significant inferior survival. The variation in copy number (CN) of 1q (CN = 3 or CN >3) had no significant impact on the survival of MM patients with 1q abnormalities. No difference was found in the outcome of 1q gain/amp patients treated with doublet or triplet regimens. Upfront autologous stem cell transplantation could eliminate the adverse prognostic effect of 1q gain but not 1q amp. The duration from diagnosis to the first time achieving very good partial response (VGPR) or better was significantly shorter in patients with 1q gain/amp (77 days vs. 100 days, p = .001). Finally, multifactor regression analysis was performed to construct a new risk stratification model in MM patients with 1q gain/amp, which was validated in the Multiple Myeloma Research Foundation CoMMpass study cohort and worked better than the Revised International Staging System and Second Revision of the International Staging System (Harrell's concordance index: 0.631 vs. 0.598 and 0.537).
Conclusions
In the setting of novel therapy, 1q gain/amp still acts as an independent adverse prognostic factor. Patients with 1q gain/amp achieved VGPR rapidly but had inferior survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Yawen Wang, Peng Liu
Zitieren
APA
Wang, Y., Xu, J., Xu, B., Li, P., Yang, Y., Wang, W., Xu, T., Maihemaiti, A., Lan, T., Wang, P., Ren, L., Zhou, C., Aihemaiti, X., & Liu, P. (2023). The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse. Cancer, 129(7), 1005-1016. https://doi.org/10.1002/cncr.34641
Vancouver
Wang Y, Xu J, Xu B, Li P, Yang Y, Wang W, et al. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse. Cancer. 2023;129(7):1005-1016. doi:10.1002/cncr.34641
BibTeX
@article{Wang2023,
author = {Wang, Yawen and Xu, Jiadai and Xu, Bei and Li, Panpan and Yang, Yang and Wang, Wenjing and Xu, Tianhong and Maihemaiti, Aziguli and Lan, Tianwei and Wang, Pu and Ren, Liang and Zhou, Chi and Aihemaiti, Xianmuseye and Liu, Peng},
title = {The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse},
journal = {Cancer},
year = {2023},
volume = {129},
number = {7},
pages = {1005--1016},
doi = {10.1002/cncr.34641}
}
EUVIMED